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Viral infections stimulate the transcription of interferon
type I, which includes IFN-alfa (IFN-a) (13 subtypes) and
IFN-b (a single substance). Hepatitis C virus (HCV) infec-
tion is remarkable by its ability to evade host antiviral
defenses; however, there is little information as to whether
endogenous IFN is activated or not in this disease. Addition-
ally, despite the fact that the various IFN-a subtypes may
differ in biological activity, there are no data concerning the
IFN-a subtypes specifically expressed in normal and dis-
eased liver tissue. Thus, we have analyzed the IFN-a
subtypes and the mRNA levels of type I IFNs in samples of
normal liver tissue and in liver from patients with chronic
hepatitis C. Similar studies were performed in peripheral
blood mononuclear cells (PBMC) from patients and con-
trols. After amplification and cloning of IFN-a cDNA, we
observed that 98 of the 100 clones from normal liver tissue
corresponded to the IFN-a5 subtype. However, in livers
with chronic hepatitis C and in PBMC from controls and
patients, a variety of subtypes, in addition to IFN-a5, were
detected, suggesting a participation of infiltrating leuko-
cytes in the production of IFN-a in livers with chronic
hepatitis C. As compared with controls, patients with
chronic hepatitis C showed a significant increase in IFN-b
mRNA in both the liver and PBMC, while IFN-a mRNA was
significantly increased in PBMC but markedly reduced in
liver tissue. In conclusion, IFN-a5 is the sole IFN-a subtype
expressed in normal liver tissue. The hepatic levels of
IFN-a are reduced in chronic hepatitis C, an event that may
favor viral persistence. (HEPATOLOGY 1999;29:1900-1904.)
Interferon alfa (IFN-a) and IFN-b, two members of the
type I IFN family, are produced by a great diversity of cells in
response to viral infections.1,2 Type I IFNs constitute the first
line of defense against viruses by displaying direct antiviral
effects and also by interacting with the cytokine cascade and
the immune system, having regulatory effects on growth and
differentiation of T cells.3,4
While IFN-b is a glycoprotein product of a single gene,
IFN-a is a family of 13 structurally related polypeptides
(subtypes), each encoded by a separate gene.5 Human IFN-a
genes are expressed constitutively in organs of normal
individuals,6,7 and show restricted cell-type expression.8 It
has been shown that the antiviral activity and immunoregulatory
properties differ among IFN-a subtypes.9 However, tissue specific-
ity and the biological role of the diverse IFN-a subtypes remain to
be determined. In particular, little is known concerning the IFN-a
subtypes expressed in normal and diseased livers.
Viral infections activate transcription of type I IFN genes.10
The promoters of IFN-a and IFN-b genes contain different
response elements.11 Functional differences between the
promoters explain, at least in part, the tissue-specific expres-
sion patterns of the two IFN subfamilies. The specificity is
achieved by the interaction of virus-induced cell-specific
factors with regulatory domains in the promoters of IFN
genes.12,13 As in other chronic viral diseases,14 the tendency of
hepatitis C virus (HCV) infection to evolve to chronicity may
depend not only on its ability to escape immunity,15,16 but also
on its capacity to deactivate the endogenous IFN system. In
fact, in vitro studies have suggested that HCV may interfere
with intracellular signaling of type I IFNs17; however, there
are no data in the literature on the possible effects of this virus
on the transcriptional expression of IFN-a and -b in vivo. A
main reason for this is technical problems, because mRNA of
type I IFN is not abundant, and techniques based on cDNA
amplification have the risk of amplifying genomic DNA along
with cDNA as a result of the fact that type I IFN genes lack
introns. In this work, we have analyzed the expression of
IFN-a subtypes in samples of normal liver tissue obtained at
laparotomy and in liver biopsies from patients with chronic
hepatitis C. In addition, we have used a sensitive and specific
polymerase chain reaction (PCR)-based technique to deter-
mine the levels of mRNA of IFN-a and -b in the liver and
peripheral blood mononuclear cells (PBMC) in patients with
chronic hepatitis C and controls to better understand the
interaction of HCV with the endogenous IFN system.
PATIENTS AND METHODS
Samples of normal liver tissue were obtained from 11 patients (8
males and 3 females; age range, 49-70 years) who underwent
laparotomy because of early stages of gastrointestinal neoplasms or
uncomplicated hydatidic cyst. These subjects had not received
anti-inflammatory or cytotoxic therapy previous to operation, and in
all cases, histological examination of the surgical biopsy showed
normal liver architecture. We also studied liver biopsies from 16
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patients with chronic hepatitis C (9 males and 7 females; age range,
24-71 years), of whom 5 had cirrhosis. Genotype 1b was found in 11
patients. Liver specimens were also taken from another control
group (n 5 12) with miscellaneous liver disorders unrelated to HCV
(cirrhosis of alcoholic or cryptogenic origin [n 5 6], hepatitis B
surface antigen–positive chronic hepatitis [n 5 5], and primary
biliary cirrhosis stage II). In this miscellaneous group, liver damage,
as estimated by the histological Knodell’s index, was similar to that
of patients with chronic HCV infection. Written consent was
obtained in all cases.
PBMC were collected from 22 healthy controls (12 females; age
range, 25-66 years) and 23 patients with chronic hepatitis C (14
males; age range, 29-69 years; 4 with cirrhosis; 21 infected with
genotype 1b). Liver biopsy for the study of IFN transcripts was
available in 8 of these patients.
In all cases, diagnosis of chronic hepatitis C was based on raised
serum transaminases for more than 6 months, positivity for anti-
HCV antibodies (second-generation enzyme-linked immunosorbent
assay; Ortho Diagnostic Systems, Raritan, NJ), presence of HCV
RNA by reverse-transcription PCR in serum, and histological
evidence of chronic hepatitis. None of the patients had received IFN
treatment at least for 1 year before the study, except 1 case in which
liver biopsy was taken 6 months after finishing treatment.
Total RNA was extracted from liver samples, and IFN-a and
IFN-b mRNA were determined by semiquantitative reverse-
transcription PCR in a Perkin-Elmer Gene Amp PCR System 2400
(Perkin Elmer, Foster City, CA). Before the reverse transcription, 2
µg of total RNA was treated with 1 U of deoxyribonuclease (DNase I
amplification grade, Gibco-BRL, Gaithersburg, MD) to remove all
the contaminating DNA. In all cases, the presence of traces of DNA
was excluded by performing control reactions without reverse
transcriptase. RNA was reverse-transcribed (60 minutes at 37°C)
with 400 U of M-MuLV reverse transcriptase (Gibco-BRL) in 40-µL
volume of 53 reverse-transcriptase buffer (250 mmol/L Tris-HCl
[pH 8.3], 375 mmol/L KCl, 15 mmol/L MgCl2), supplemented with
5 mmol/L dithiothreitol, 0.5 mmol/L deoxynucleoside triphosphate
(Boehringer Mannheim, Mannheim, Germany), 48 U ribonuclease
inhibitor (Promega Corporation, Madison, WI), and 400 ng random
hexamers (Boehringer Mannheim, Mannheim, Germany). After
heating (95°C, 1 minute) and quick-chilling on ice, an aliquot of 10
µL (0.5 µg) of the complementary DNA pool was used for PCR
amplification of IFN-a or IFN-b in 50 µL of 103 PCR buffer (160
mmol/L [NH4]2SO4, 670 mmol/L Tris-HCl [pH 8.8], 0.1% Tween-
20), containing upstream and downstream primers (40 ng each for
IFN-a and 60 ng each for IFN-b), 1.2 mmol/L MgCl2, and 2 U of
Biotaq DNA polymerase (Bioline, London, UK). Blank reactions
with no RNA were performed in all experiments. As internal control
for each sample, PCR amplification of a fragment of b-actin cDNA
(using a 10-µL aliquot of the cDNA pool) was performed. IFN-a
cDNA fragments were amplified by 30 or 33 cycles (PBMC or liver,
respectively) (94°C, 60°C, and 72°C for 20, 15, and 30 seconds for
each step, respectively), IFN-b was amplified by 30 or 35 cycles
(PBMC or liver, respectively) (94°C, 58°C, and 72°C for 20, 15, and
30 seconds for each step, respectively), and b-actin was amplified by
18 or 25 cycles (PBMC or liver, respectively) (94°C, 55°C, and 72°C
for 20, 15, and 30 seconds for each step, respectively), a protocol
that avoided interference of the plateau effect. We used universal
primers designed to amplify all IFN-a subtypes. Oligonucleotides
(58-38) d(TCCATGAGATGATCCAGCAG) and d(ATTTCTGCTCT-
GACAACCTCCC) were the upstream and downstream primers,
respectively, for amplification of a 274-bp fragment from human
IFN-a cDNA18 that is located between nucleotides 240-514.19
Primers were designed to obtain the same amplification efficiency
for all IFN-a subtypes. The two primers correspond to the two most
conserved regions among all subtypes. The sequence for annealing
of the downstream primer is identical for all of them. The annealing
sequence of the upstream primer is the same for subtypes 2, 4, 5, 7,
8, 10, 16, 17, and 21, and it differs in only one nucleotide in
subtypes 1, 14, and 22 (this change does not occur in the 38 end of
the primer). Also, no other internal regions for annealing of the
primers exist in the different subtypes (Oligo 4.05 Primer Analysis
Software, National Bioscience Inc., Plymouth, MN). d(TCTAGCAC-
TGGCTGGAATGAG) and d(GTTTCGGAGGTAACCTGTAAG) were
the primers used to amplify a 276-bp fragment from human IFN-b
cDNA that is located between nucleotides 349-625.20 d(TCTACAAT-
GAGCTGCGTGTG) and d(GGTGAGGATCTTCATGAGGT) were
the primers used for amplification of a 314-bp fragment (nucleotides
1319-2079) from the reported human b-actin gene sequence.21
Identification of IFN-a subtype transcripts was performed by
cloning the PCR products using the TOPO TA cloning kit (Invitro-
gen, Carlsbad, CA). Clones from each insert were sequenced in ABI
PRISM 310 Genetic Analyzer (Perkin Elmer) using the dye Rhoda-
mine terminator cycle sequencing kit (Perkin Elmer).
After PCR amplification, 20-µL aliquots of the PCR reactions
were electrophoresed in 2% agarose gel stained with ethidium
bromide. The bands were visualized with an ultraviolet lamp and
analyzed with commercial software (Molecular Analyst/PC, Bio-Rad,
Hercules, CA). Finally, values corresponding to IFN-a or IFN-b
mRNA were normalized to those of b-actin mRNA, and results were
expressed as the ratio of IFN-a or IFN-b to b-actin. When IFN-a
and IFN-b mRNA values were normalized to those of b-actin
mRNA, it was assumed that b-actin mRNA was constantly expressed
in patients with chronic hepatitis C, normal controls, and patients
with other liver diseases unrelated to HCV, both in PBMC and liver.
In fact, we compared b-actin mRNA values among the three groups
studied, and no differences were observed (data not shown).
Constant expression of b-actin mRNA was also found in a previ-
ously reported series of patients and controls in which the same
semiquantitative PCR procedure was used to analyze tumor necrosis
factor a mRNA values in liver and PBMC.22
Validation experiments on PCR assays using known quantities of
total RNA showed linearity of the counts of amplification bands
from 0.125 to 1 µg in both liver and PBMC for IFN-a, IFN-b, and
b-actin. Thus 0.5 µg was chosen as the suitable amount of total RNA
to avoid the plateau effect. To analyze whether changes in IFN-a or
IFN-b mRNA levels resulted in changes in the ratio of IFN-a or
IFN-b PCR product/b-actin PCR product, we performed reverse-
transcription PCR with 0.1 µg of total normal liver RNA containing
serial dilutions of known quantities of IFN-a or IFN-b riboprobes,
which were obtained by run-off transcription of a plasmid that
contained a 274- and 276-bp inserts from the human IFN-a and -b
cDNA. With increasing amounts of IFN-a and -b riboprobe used in
the reaction, we obtained a progressive increase in the IFN-a or
-b/b-actin ratio (data not shown). The coefficient of interassay
variation for IFN-a/b-actin and IFN-b/b-actin was 15% and 12%,
respectively. The identity of the PCR product from IFN-a and IFN-b
cDNA amplification was verified by automatic sequencing (ABI
PRISM 310 Genetic Analyzer, Perkin Elmer).
Detection, quantitation, and genotyping of HCV RNA was per-
formed as previously described.22,23
Results of IFN-a and IFN-b are given as mean 6 SEM. Normality
was assessed with the Shapiro-Wilks test. Statistical analysis of
IFN-a and IFN-b levels in PBMC and in the liver were performed
using nonparametric (Kruskal-Wallis and Mann-Whitney U) tests.
Associations between quantitative variables were studied with
Spearman’s correlation coefficient. Qualitative variables were ana-
lyzed with the Fisher exact test. All P values were two-tailed. SPSS
6.0 for Windows was used for the statistical analysis.
RESULTS
IFN-a Subtypes in the Liver and in PBMC. RNA was extracted
from liver samples and PBMC, and IFN-a cDNA was ampli-
fied with universal primers for all IFN-a subtypes. After
cloning and sequencing of PCR products, we found that 98 of
the 100 clones derived from six samples of normal liver tissue
showed the sequence corresponding to IFN-a5 subtype
(Table 1). We also sequenced 98 clones obtained from liver
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biopsies from 7 patients with chronic hepatitis C. Of these,
only 81 corresponded to IFN-a5 (P , .001 as compared with
samples of normal liver tissue). In the liver of patients with
chronic hepatitis C, other subtypes (a1, a4, a17, and a21),
in addition to a5, were represented (Table 1), probably
reflecting the production of IFN-a not only by hepatocytes,
but also by infiltrating leukocytes.
As shown in Table 2, a combination of different IFN-a
subtypes was found in PBMC from patients with HCV
infection and healthy controls. In PBMC from healthy sub-
jects, 15 of 43 clones analyzed corresponded to IFN-a5,
whereas this subtype was found in 31 of 45 clones from
PBMC of patients with chronic hepatitis C (P , .005).
Transcriptional Expression of IFN-a and -b in the Liver and in
PBMC. IFN-a and IFN-b mRNA levels were measured in
PBMC and liver tissue from patients with chronic hepatitis C
and controls (Table 3). The levels of IFN-a mRNA were
significantly increased in PBMC from chronic hepatitis C
patients as compared with normal controls. However, IFN-a
mRNA values were found to be significantly reduced in the
liver of patients with chronic hepatitis C with respect to
samples of normal liver tissue and also with respect to values
found in a miscellaneous group of chronic liver diseases. The
five cases with chronic hepatitis B included in the disease
control group had values of IFN-a mRNA in the liver (0.33 6
0.15) similar to those found in normal hepatic tissue and
significantly higher than patients with chronic hepatitis C
(P , .02).
As was the case for IFN-a, the levels of IFN-b mRNA were
raised in PBMC from patients with chronic hepatitis C as
compared with healthy subjects (Table 3). However, in
contrast to IFN-a, IFN-b mRNA was significantly increased
in the liver of patients with chronic HCV infection as
compared with those found in specimens of normal liver
tissue and also as compared with those observed in biopsies
from patients with miscellaneous liver disorders (Table 3).
IFN-b mRNA was not increased in hepatic tissue from the 5
patients with chronic hepatitis B included in the disease
control group (1.02 6 0.74) as compared with values found
in normal liver tissue.
Figure 1 shows an example of the amplification bands of
IFN-a, IFN-b, and b-actin cDNAs obtained from specimens
of normal liver tissue and liver biopsies from patients with
chronic hepatitis C. In each case, the same RNA preparation
was used for reverse transcription and amplification of the
three gene products. It can be clearly seen that while the
intensity of the b-actin band is similar in all cases, the band
corresponding to IFN-a is decreased, while that of IFN-b is
increased in livers with chronic HCV infection as compared
with samples of normal liver tissue.
We found that in patients with chronic hepatitis C, IFN-b
TABLE 1. IFN-a Subtypes in Normal Liver Tissue and in Liver From
Patients With Chronic Hepatitis C
No. of Clones Tested a1 a4 a5 a10 a17 a21 a22
Normal Liver
Total 100 0 0 98 1 0 0 1
Patients
P 1 16 0 0 12 0 2 2 0
P 2 15 0 1 10 0 0 4 0
P 3 20 0 0 20 0 0 0 0
P 4 5 0 0 5 0 0 0 0
P 5 16 2 1 10 0 0 3 0
P 6 14 0 1 12 0 0 1 0
P 7 12 0 0 12 0 0 0 0
Total 98 2 3 81 0 2 10 0
NOTE. Normal liver are samples from 6 normal liver tissues obtained at
laparotomy. P 1-7 are samples from 7 different patients with chronic hepatitis
C. Figures represent the number of cDNA clones showing the sequence
corresponding to the indicated IFN-a subtype.
TABLE 2. IFN-a Subtypes in PBMC From Healthy Controls and From
Patients With Chronic Hepatitis C
No. of Clones Tested a1 a2 a4 a5 a7 a8 a10 a16 a21 a22
Controls
Total 43 14 1 1 15 1 2 2 0 6 1
Patients
P 1 8 0 0 0 7 0 0 0 0 1 0
P 2 9 0 0 0 5 0 0 0 0 4 0
P 3 11 0 0 2 4 1 0 1 2 0 1
P 4 8 0 0 0 7 0 0 0 0 1 0
P 8 9 0 1 0 8 0 0 0 0 0 0
Total 45 0 1 2 31 1 0 1 2 6 1
NOTE. Controls are PBMC samples from 5 healthy subjects; P1-8 are
PBMC samples from 5 different patients with chronic hepatitis C. Figures
represent the number of cDNA clones showing the sequence corresponding
to the indicated IFN-a subtype.
TABLE 3. mRNA Levels of Type I IFNs in the Liver and in PBMC From
Patients With Chronic Hepatitis C and From Controls
Liver PBMC
Normal
Liver Tissue
(n 5 11)
Chronic
Hepatitis C
(n 5 16)
Other Liver
Diseases
(n 5 12)
Healthy
Controls
(n 5 22)
Chronic
Hepatitis C
(n 5 23)
IFN-a 0.43 6 0.12 0.12 6 0.03* 0.24 6 0.03 0.88 6 0.17 2.53 6 0.37†
IFN-b 1.03 6 0.16 1.73 6 0.23‡ 0.92 6 0.17 0.76 6 0.09 1.41 6 0.16†
NOTE. Values are expressed as the ratio IFN-a or IFN-b mRNA/b-actin
mRNA. Data are given as means 6 SEM.
*P , .01 vs. normal liver and other liver diseases.
†P , .001 vs. healthy controls.
‡P , .05 vs. normal liver and other liver diseases.
FIG. 1. Amplification bands of IFN-a, IFN-b, and b-actin cDNAs
obtained from specimens of normal liver tissue (N1-N4) and liver biopsies
from patients with chronic hepatitis C (P1-P4). It can be seen that the band
corresponding to IFN-a is decreased and that of IFN-b is increased in livers
with chronic HCV infection as compared with samples of normal liver tissue;
in contrast, the intensity of the b-actin band is similar in all cases. MW,
molecular weight.
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mRNA values correlated directly with the histological Knodell’s
index of liver damage (r 5 .66; P , .01) and with serum
aspartate aminotransferase (r 5 .64; P , .01). Although the
transcriptional expression of IFN-a in the liver was substan-
tially reduced in chronic hepatitis C, a significant correlation
between hepatic IFN-a mRNA levels and the Knodell’s index
(r 5 .54; P , .05) was also encountered, suggesting a
participation of the mononuclear infiltrate in the production
of IFN transcripts. We found no correlation between IFN-a
or IFN-b mRNA values (in the liver or in PBMC) and the titer
of HCV RNA in serum.
DISCUSSION
In response to viral infections, IFN-a is produced by a great
diversity of cell types including mononuclear cells, polymor-
phonuclear leukocytes, hepatocytes, fibroblasts, Kupffer cells,
and dendritic cells.24-28 IFN-b is synthesized mainly by
fibroblasts, epithelial cells, and mononuclear cells.29,30 On the
other hand, different studies have shown that IFN-a is
constitutively expressed in a variety of tissues such as liver,
spleen, kidney, pancreas, and PBMC.6,7,24 These findings
challenge the idea that IFNs are produced only in response to
viral infection and point to an as-yet-unclear biological
function of IFNs in normal tissues. The present study shows
that normal liver tissue expresses almost exclusively the
IFN-a5 subtype. In contrast with this restriction to only one
IFN-a subtype, other subtypes, similar to those found in
PBMC, were observed in livers from patients with chronic
hepatitis C, possibly reflecting the participation of infiltrating
mononuclear cells in the production of IFN-a transcripts.
Interestingly, in patients with chronic HCV infection, the
pattern of IFN-a subtypes in PBMC was different to that of
normal individuals with a preponderance of subtype 5, a
finding of unknown biological significance.
The restriction of IFN-a expression in the liver to only
IFN-a5 raises questions about the specific physiological
activities of this subtype. In fact, it has been shown that,
although IFN-b and all subtypes of IFN-a bind to the same
receptor, differences in intracellular signaling and biological
effects exist among them in specific cell types.9,31 It is
therefore conceivable that IFN-a5 might exert antiviral and
other biological effects on liver cells, which could differ from
those elicited by other IFN-a subtypes.
HCV infection is characterized by a pronounced tendency
to become chronic. This virus has developed the ability to
evade both the IFN system and the immune response through
mechanisms that remain unclear. In this study, we show that
patients with chronic HCV infection exhibit an enhanced
expression of IFN-b in both the liver and PBMC, as expected
for a virus that can infect both hepatocytes and mononuclear
cells.32 However, the effects of HCV on IFN-a are different. In
patients with chronic hepatitis C, IFN-a mRNA levels are
increased in PBMC but markedly reduced in the liver. Thus,
HCV infection causes opposite changes of IFN-a and IFN-b
in hepatic tissue, decreasing the expression of the former,
while increasing the latter. This finding might be explained
by the fact that IFN-a and IFN-b are induced in viral
infections by different mechanisms,11 and it is possible that
HCV may interfere specifically with the induction of IFN-a.
The selective interference of HCV with IFN-a expression
might indicate a relevant role of IFN-a in controlling this
viral infection. Because increased production of IFN-a by
hepatocytes has been shown to be associated with resolution
of acute viral hepatitis,25 one of the strategies by which HCV
succeeds in establishing persistent infection might be through
mechanisms that impair the expression of IFN-a in the liver.
The characterization of the HCV gene products possessing
the ability to block the transcriptional machinery of IFN-a
will undoubtedly help to understand the pathophysiology of
this infection and its tendency to chronicity.
An additional observation in this article is the fact that
HCV infection is associated with increased values of IFN-a
mRNA in PBMC, while the levels of this transcript are
reduced in liver parenchyma. To explain this finding, it
should be remembered that IFN-a genes have a regulatory
domain within the virus-response element that determines
cell-specific gene expression.8 Thus, it can be thought that
interaction of HCV with different cell transcription factors in
PBMC and in the liver can arbitrate the opposite changes in
IFN-a gene expression found in these two tissues in chronic
HCV infection.
In patients with chronic hepatitis C, we observed a positive
correlation between the Knodell index of histological hepatic
damage and the level of expression of type I IFNs in the liver.
This observation might be explained by the participation of
infiltrating mononuclear cells in the production of IFN-a and
-b. Indeed, studies using monoclonal antibodies have shown
the presence of IFN-positive cells in the mononuclear infil-
trate of liver biopsies from patients with chronic hepatitis B26
and C.27 These investigations have demonstrated a good
correlation between the number of IFN-positive cells and the
intensity of the histological liver damage.
Finally, considering that IFN-a5 is the subtype mainly
expressed in hepatic tissue and that IFN-a is decreased in the
liver of patients with chronic HCV infection, it is tempting to
speculate that IFN-a5 might have a role in the treatment of
chronic hepatitis C. This suggestion is supported by studies
showing that IFN-a5 is endowed with potent antiviral and
antiproliferative properties.9 At present, lymphoblastoid IFN
(a mixture of subtypes with only a small proportion of
IFN-a5) and the two recombinant IFNs, IFN-a2a and IFN-
a2b, are used to treat chronic hepatitis C, but fewer than 30%
of treated patients exhibit sustained biochemical and virologi-
cal response.33 Thus, more efficient therapies are urgently
needed. Our data may stimulate further work on the mecha-
nisms used by HCV to impair transcriptional activation of
IFN-a in the liver and on the effects of IFN-a5, the
liver-specific IFN-a subtype, on HCV replication.
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